Evome Medical Technologies Inc. Share Price

Equities

BRTL

CA30053H1055

Advanced Medical Equipment & Technology

Market Closed - Toronto S.E. 01:11:52 27/04/2024 am IST 5-day change 1st Jan Change
0.195 CAD -7.14% Intraday chart for Evome Medical Technologies Inc. -20.41% -7.14%

Financials

Sales 2024 * 62.21M 45.48M 3.79B Sales 2025 * - Capitalization 15.38M 11.25M 938M
Net income 2024 * -5M -3.66M -305M Net income 2025 * - EV / Sales 2024 * 0.25 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-3.9 x
P/E ratio 2025 *
-
Employees 200
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.47%
More Fundamentals * Assessed data
Dynamic Chart
Evome Medical Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Riddell, Inc. acquired Simbex, LLC from Evome Medical Technologies Inc. for $3.6 million. CI
Evome Medical Technologies Inc. Announces Board Changes CI
Evome Medical Technologies Inc. Announces CFO Changes CI
Evome Medical Technologies Inc. Announces Change of Principal Accounting Officer CI
Salona Global Medical Device Corporation will Change its Ticker to EVMT from SGMD CI
Salona Global Medical Device Corporation will Change its Name to Evome Medical Technologies Inc CI
Salona Global Finalizes Name Change to Evome Medical Technologies MT
Salona Global Medical Device Corporation Announces Leslie Cross Retires from its Board of Directors CI
Salona Global Announces Exclusive Partnership with U.S. Military Veteran Focused Distribution Company MT
Salona Global Medical Device Corporation Executes Exclusive Distribution Agreement with Veteran Medical Solutions, LLC CI
Salona Global Medical Device Corporation Announces Resignation of Kyle L. Wilks as Board of Directors CI
Salona Global Announces Debut of the Biodex Reactive Step Trainer MT
Salona Global Medical Device Corporafion Announces the Debut of the Biodex Reac Five Step Trainer CI
Salona Global Medical Device Corporation Showcases Biodex Products at Medica Trade Fair in Dusseldorf, Germany; Expanding Access to International Markets CI
More news
1 day-7.14%
1 week-20.41%
Current month-13.33%
1 month-11.36%
3 months-25.00%
6 months-7.14%
Current year-7.14%
More quotes
1 week
0.20
Extreme 0.195
0.26
1 month
0.20
Extreme 0.195
0.30
Current year
0.15
Extreme 0.15
0.30
1 year
0.15
Extreme 0.15
0.33
3 years
0.15
Extreme 0.15
1.49
5 years
0.11
Extreme 0.1085
1.49
10 years
0.11
Extreme 0.1085
3.01
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 13/23/13
Director/Board Member 60 01/20/01
Sales & Marketing - 01/22/01
Members of the board TitleAgeSince
Director/Board Member 60 01/20/01
Director/Board Member - 14/02
Chairman 73 16/20/16
More insiders
Date Price Change Volume
26/24/26 0.195 -7.14% 326,296
25/24/25 0.21 -8.70% 152,500
24/24/24 0.23 0.00% 258,401
23/24/23 0.23 -4.17% 41,065
22/24/22 0.24 -2.04% 32,504

Delayed Quote Toronto S.E., April 27, 2024 at 01:11 am IST

More quotes
Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.195 CAD
Average target price
1.15 CAD
Spread / Average Target
+489.74%
Consensus

Annual profits - Rate of surprise